Javier Cortes, MD, PhD, discusses results from the PHERGain study, evaluating chemotherapy de-escalation strategies in HER2-positive early breast cancer, presented at the 2023 ASCO Annual Meeting.
Javier Cortes, MD, PhD, discusses results from the PHERGain study, evaluating chemotherapy de-escalation strategies in HER2-positive early breast cancer, presented at the 2023 ASCO Annual Meeting.
Javier Cortes, MD, PhD,...